PUMA BIOTECHNOLOGY INC (PBYI) Stock Price

PBYIStock

$9.83+81.70%52W

Market Cap$507.43M

P/E16.31x

PEG Ratio—

Div yield—

Beta1.37

PBYI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)19.95%

Price vs S&P 500 (4W)3.83%

VGM Score63.14

P/E Ratio (Annual)16.31x

P/CF (Annual)12.14x

Book Value / Share (Quarterly)$2.71

P/TBV (Annual)3.37x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)0.05%

Cash Flow / Share (Quarterly)$0.81

Price vs S&P 500 (YTD)53.28%

Gross Margin (TTM)74.83%

Net Profit Margin (TTM)11.55%

EPS (TTM)$0.52

10-Day Avg Trading Volume0.33M

EPS Excl Extra (TTM)$0.52

Revenue Growth (5Y)0.29%

EPS (Annual)$0.61

ROI (Annual)20.35%

Gross Margin (Annual)74.53%

Net Profit Margin (5Y Avg)4.89%

Cash / Share (Quarterly)$1.84

P/E Basic Excl Extra (TTM)18.99x

Revenue Growth QoQ (YoY)7.75%

P/E Normalized (Annual)16.31x

ROA (Last FY)14.38%

Revenue Growth TTM (YoY)-2.86%

EBITD / Share (TTM)$0.79

ROE (5Y Avg)-66.97%

Operating Margin (TTM)13.16%

Cash Flow / Share (Annual)$0.83

P/B Ratio3.66x

P/B Ratio (Quarterly)2.98x

Net Income / Employee (Annual)$173,800

EV / Revenue (TTM)2.04x

Net Interest Coverage (TTM)15.07x

ROA (TTM)13.28%

EPS Growth QoQ (YoY)33.30%

EV / EBITDA (TTM)11.51x

EPS Incl Extra (Annual)$0.61

Current Ratio (Annual)2.00x

Quick Ratio (Quarterly)2.57x

3-Month Avg Trading Volume0.33M

52-Week Price Return81.70%

EV / Free Cash Flow (Annual)11.28x

P/E Incl Extra (TTM)18.99x

Revenue / Employee (TTM)$1,291,900

Tangible BV / Share (Quarterly)$2.00

P/S Ratio (Annual)2.22x

Asset Turnover (Annual)1.06x

52-Week High$10.72

Operating Margin (5Y Avg)8.42%

EPS Excl Extra (Annual)$0.61

CapEx CAGR (5Y)-67.65%

26-Week Price Return29.85%

Quick Ratio (Annual)1.89x

13-Week Price Return15.24%

Total Debt / Equity (Annual)0.17x

Current Ratio (Quarterly)2.91x

Enterprise Value$470.89M

Revenue / Share Growth (5Y)-4.53%

Asset Turnover (TTM)1.15x

Book Value / Share Growth (5Y)23.62%

Revenue / Employee (Annual)$1,275,800

Inventory Turnover (Annual)8.17x

Pretax Margin (Annual)15.67%

Cash / Share (Annual)$1.93

3-Month Return Std Dev44.87%

Gross Margin (5Y Avg)74.13%

Net Income / Employee (TTM)$149,300

EBITDA Interim CAGR (5Y)52.87%

ROE (Last FY)23.87%

Net Interest Coverage (Annual)15.07x

EPS Basic Excl Extra (Annual)$0.61

P/FCF (TTM)12.33x

Receivables Turnover (TTM)7.71x

EV / Free Cash Flow (TTM)11.44x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.52

Receivables Turnover (Annual)5.33x

ROI (TTM)18.42%

P/S Ratio (TTM)2.19x

Pretax Margin (5Y Avg)4.92%

Revenue / Share (Annual)$4.51

Tangible BV / Share (Annual)$1.76

Forward P/E27.36x

Free OCF CAGR (5Y)11.98%

Price vs S&P 500 (52W)66.17%

P/E Ratio (TTM)18.99x

EPS Growth TTM (YoY)-47.40%

Year-to-Date Return65.21%

5-Day Price Return-4.47%

EPS Normalized (Annual)$0.61

ROA (5Y Avg)5.02%

Net Profit Margin (Annual)13.62%

Month-to-Date Return-1.01%

Cash Flow / Share (TTM)$0.31

EBITD / Share (Annual)$0.95

Operating Margin (Annual)16.33%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)12.33x

ROI (5Y Avg)-2.75%

P/E Excl Extra (TTM)18.99x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$0.52

P/TBV (Quarterly)4.05x

P/B Ratio (Annual)2.30x

Inventory Turnover (TTM)5.31x

Pretax Margin (TTM)13.48%

Book Value / Share (Annual)$2.59

Price vs S&P 500 (13W)12.55%

Beta1.37x

P/FCF (Annual)12.16x

Revenue / Share (TTM)$4.40

ROE (TTM)20.85%

52-Week Low$4.58

vGradeC

gGradeC

mGradeA

vgmGradeB

PBYI Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	$0.07	$0.20	+185.71%(+$0.13)
Q1 2026	May 7, 2026	-$0.13	-$0.04	+69.23%(+$0.09)
Q4 2025	Feb 26, 2026	$0.23	$0.29	+26.09%(+$0.06)
Q3 2025	Nov 6, 2025	$0.09	$0.21	+133.33%(+$0.12)
Q2 2025	Aug 7, 2025	$0.07	$0.15	+114.29%(+$0.08)

PBYI Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

2.17

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PBYIPUMA BIOTECHNOLOGY INC	C	C	A	2.2x	-2.9%	74.8%	—	$9.83
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About PUMA BIOTECHNOLOGY INC

Puma Biotechnology is an oncology-focused biopharmaceutical company that commercializes NERLYNX, an oral medication for HER2-positive breast cancer, and is developing alisertib, an aurora kinase A inhibitor. The company targets improvements in cancer treatment outcomes through its portfolio of targeted therapies.

PBYI Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeAMC

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

PBYI Insider Transactions

SellSep 14, 2026
CESANO ALESSANDRA
Director
Shares: 62,150Value: $566,994
SellSep 14, 2026
WILSON TROY EDWARD
Director
Shares: 5,000Value: $45,500

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

TROXTRONOX LIMITED CL A ORDINARY SHARESIndustrial Chemicals
ETRAElectra Therapeutics, Inc. Common stockBiological Products
VALNValneva SE American Depositary SharesBiological Products
PROKProKidney Corp. Class A Ordinary SharesBiological Products
ENTXEntera Bio Ltd. Ordinary SharesBiological Products
LXFRLuxfer Holdings PLC Ordinary SharesIndustrial Chemicals
RGNXREGENXBIO Inc.Biological Products
ALLOAllogene Therapeutics, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

2.2

Sell

Consensus rating

52-Week Range

Low$4.58

High$10.72